Biotech · Private company
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Track this companyFree. Adds POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- [Lu-177]-PNT2002Phase 3 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- AbirateronePhase 3 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- EnzalutamidePhase 3 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- [Ga-68]-PNT6555Phase 1 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- [Lu-177]-PNT6555Phase 1 · Pancreatic Ductal AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)PHASE1 · TERMINATED · started Jul 13, 2022ClinicalTrials.gov NCT05432193 · fetched Nov 12, 2026
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 25, 2021ClinicalTrials.gov NCT04647526 · fetched Nov 12, 2026